| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | RNA-Based Therapies | Rare Diseases | ||
IND Submission example | IND | — | Subscribe to access the data. | RNA-Based Therapies | Rare Diseases | ||
IND Submission example | IND | — | Subscribe to access the data. | RNA-Based Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Atrium Therapeutics, Inc.$11.57
+0.08 (+0.7%)
B 63Pipeline Score Undervalued Biotech · Clinical
Market Cap
223.91 M
EPS
-
P/E Ratio
-
Value Trade
1.83 M
SEC Financials
Q1 2026Dilution Risk
Revenue
19.64 M
R&D Expenses
16.66 M
Operating CF
-31.14 M
Total Assets
292.36 M
Total Liabilities
58.26 M
Equity
234.10 M
D/E Ratio
12,345
-2.89 %
Week
-3.82 %
1 Month
-10.22 %
3 Month
-10.22 %
6 Month
-10.22 %
5 Year
-10.22 %
All Time
Cash Data
Cash Position
267.85 M
Monthly Burn
10.38 M
Runway
23.3 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
82.82 K
52 Week Range
11.95 - 16.77
% held by Insiders
0.22 %
% held by Institutions
87.94 %
Enterprise Value
-41.26 M
Total Shares
17.10 M
Short %
22.48 %
Float Shares
15.97 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Atrium Therapeutics, Inc.
511Total events
13Upcoming
107Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 2
TBD
T2First Patient Dosed
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
▲IND ClearanceIND
Subscribe to view catalyst details
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
B63
Pipeline Score $907M
Pipeline ValueUndervalued
Valuation Signal12
Drugs Scored4.1x
rNPV / MCap Top 92%
Micro Cap (rank 74 of 913)
Percentile RankAtrium Therapeutics, Inc. holds a solid B-grade pipeline (63/100), with $4.2B risk-adjusted pipeline value, led by Nivolumab in Multiple Myeloma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nivolumab Small molecule | Multiple Myeloma | Phase 2 | NCT06523621 | 19% | $876M | ACTIVE NOT_RECRUITING | 1 | - | - | Dec 1, 2028 | - | May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Del-zota BreakthroughFast TrackOrphan+1 | Duchenne muscular dystrophy (DMD) | — | 2026-02-26 | Near Normalization of CK Levels | Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Read More | |
Del-zota BreakthroughFast TrackOrphan+1 | Duchenne muscular dystrophy (DMD) | — | 2026-02-26 | Near Normalization of CK Levels | Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Read More | |
Del-zota BreakthroughFast TrackOrphan+1 | Duchenne muscular dystrophy (DMD) | — | 2026-02-26 | Near Normalization of CK Levels | Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RNA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RNA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RNAAtrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
Atrium Therapeutics has received FDA clearance for its Investigational New Drug application for ATR 1072, aimed at treating PRKAG2 syndrome. The Corventis™ Phase 1/2 trial will assess the safety and efficacy of ATR 1072, which utilizes RNA technology to address the underlying genetic causes of the disease. The trial is expected to enroll its first participant by the end of 2026, with initial data anticipated in 2027.
Read more →RNAAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics announced the awarding of inducement grants to eight newly hired non-executive employees under its 2026 Employment Inducement Incentive Award Plan. The grants include non-qualified stock options and restricted stock units, which will vest over time contingent on continued employment. This initiative aims to attract talent in alignment with Nasdaq regulations.
Read more →RNAAtrium Therapeutics Reports First Quarter 2026 Financial Results
Atrium Therapeutics reported its Q1 2026 financial results, showcasing a strong start as an independent company. The firm highlighted a successful collaboration with Bristol Myers Squibb, earning a $15 million milestone payment. Atrium is advancing its lead programs, ATR 1072 and ATR 1086, towards clinical trials, supported by a robust cash position of $267.8 million.
Read more →RNAAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Atrium Therapeutics has secured a $15 million milestone payment from Bristol Myers Squibb following the successful delivery of a development candidate for a cardiology indication. This payment is part of a larger collaboration focused on RNA-based therapies for cardiovascular diseases. Atrium's CEO emphasized the importance of this milestone in advancing their RNA delivery platform and commitment to innovative therapies.
Read more →RNA▼ -5.4%on this newsshared move
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 20, 2026
Atrium Therapeutics announced the award of inducement grants to seven newly hired non-executive employees under its 2026 Employment Inducement Incentive Award Plan. The grants include non-qualified stock options for 101,250 shares and restricted stock units for 50,625 shares, aimed at incentivizing new talent. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to enhancing its workforce.
Read more →RNA▼ -5.4%on this newsshared move
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics has announced the awarding of inducement grants to seven new non-executive employees under its 2026 Employment Inducement Incentive Award Plan. The grants include non-qualified stock options and restricted stock units, aimed at incentivizing new hires. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to enhancing its workforce.
Read more →RNA▼ -79.7%on this news
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences will present at the 2026 MDA Clinical & Scientific Conference, showcasing an oral presentation on the Del-zota treatment for Duchenne muscular dystrophy (DMD) and six poster presentations. The conference is scheduled for March 8-11, 2026, in Orlando, Florida. Additionally, Avidity will host an industry forum lunch discussing biomarker advancements in rare neuromuscular diseases.
Read more →RNA▼ -79.7%on this newsshared move
INFORMATION STATEMENT Atrium Therapeutics, Inc. Distribution of Common Stock $0.001 par value This information statement is being furnished to existing stockholders of Avidity Biosciences, Inc. ("Avidity") in connection
Avidity Biosciences, Inc. is set to distribute shares of Atrium Therapeutics, Inc. to its stockholders as part of a reorganization and spin-off transaction. This distribution involves the transfer of Avidity's early-stage precision cardiology assets to Atrium, allowing Avidity to retain other assets. Avidity stockholders will receive one share of Atrium for every ten shares they hold, and the transaction is subject to several conditions. Furthermore, Atrium's common stock will be listed on The Nasdaq Global Select Market under the ticker 'RNA'.
Read more →RNAAvidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences has announced plans to adjourn its special meeting of stockholders originally scheduled for February 23, 2026, and reconvene it on February 26, 2026. This adjournment is to allow additional time for the distribution of Atrium Therapeutics shares, which is a condition for the merger with Novartis AG. The merger is expected to close on February 27, 2026.
Read more →RNAThe New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
The Phase 1/2 MARINA trial results of delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1) have been published in The New England Journal of Medicine. The trial demonstrated that del-desiran effectively delivered siRNA, resulting in a significant reduction of DMPK mRNA and improvements across various measures of muscle function and patient-reported outcomes. While the safety profile was generally acceptable, two severe adverse events were reported. The ongoing Phase 3 HARBOR trial aims to further assess del-desiran's efficacy as a potential treatment for this progressive disease.
Read more →RNAAvidity Biosciences Announces Expected Record Date for Spin-Off
Avidity Biosciences has announced February 12, 2026, as the record date for the distribution of shares of Atrium Therapeutics, Inc. to Avidity shareholders. This distribution is part of the planned acquisition by Novartis AG and the Spin-Off of Avidity's early-stage precision cardiology programs. The completion of these transactions is contingent on certain conditions, including stockholder approval.
Read more →RNAAvidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
Avidity Biosciences has announced a Managed Access Program for del-zota, an investigational therapy for Duchenne muscular dystrophy mutations amenable to exon 44 skipping. The program aims to provide eligible patients with access to del-zota under an FDA-authorized treatment protocol. A BLA submission for accelerated approval is planned for 2026 following positive clinical trial results.
Read more →RNAAvidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
Avidity Biosciences reported its Q3 2025 financial results, highlighting a merger agreement with Novartis valued at $12 billion. The company anticipates a successful BLA submission for del-zota in 2026, supported by positive clinical data. Avidity maintains a strong financial position with approximately $1.9 billion in cash. However, it also reported a significant net loss for the quarter.
Read more →RNA▲ +42.4%on this news
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
Avidity Biosciences has entered into a definitive agreement to be acquired by Novartis AG for USD 72.00 per share, totaling approximately USD 12 billion. The deal includes the spin-off of Avidity's early-stage precision cardiology programs into a new company, SpinCo, which will be led by Kathleen Gallagher. The transaction is expected to close in the first half of 2026, pending regulatory approvals and other customary conditions.
Read more →RNAAvidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences, Inc. announced its participation in an upcoming investor conference, where management will engage in a panel discussion. The company focuses on developing Antibody Oligonucleotide Conjugates (AOCs™) aimed at treating rare muscle diseases and advancing its pipeline in cardiology and immunology. A live webcast of the event will be available on their website.
Read more →RNAAvidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
Avidity Biosciences announced a successful pre-BLA meeting with the FDA regarding del-zota, an investigational drug for Duchenne muscular dystrophy. The company plans to submit a BLA in Q1 2026, having adjusted the timeline to provide additional data requested by the FDA. The meeting was described as collaborative, providing a clear path for the submission process.
Read more →RNAAvidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
Avidity Biosciences will present late-breaking data on del-zota at the 30th Annual World Muscle Society Congress. The data indicates a reversal of disease progression in DMD44 patients treated for one year. Del-zota is still investigational and has not received FDA approval, with its safety and efficacy yet to be confirmed.
Read more →RNAAvidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Avidity Biosciences has successfully closed an upsized public offering of 17.25 million shares, raising $690 million. The offering included an additional 2.25 million shares due to underwriters' full exercise of their option. The proceeds will support the development of late-stage clinical programs and expand commercial infrastructure. Avidity is focused on advancing its innovative RNA therapeutics.
Read more →RNA▲ +9%on this newsshared move
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
Avidity Biosciences has announced the pricing of its upsized public offering, selling 15 million shares at $40 each, expected to generate $600 million in gross proceeds. The offering is set to close around September 15, 2025, and will fund the development of late-stage clinical programs and enhance commercial capabilities. Avidity's innovative AOC platform aims to revolutionize RNA therapeutics.
Read more →RNA▼ -11.6%on this newsshared move
Avidity Biosciences Announces Proposed Public Offering of Common Stock
Avidity Biosciences has announced a proposed public offering of $500 million in common stock, with an additional $75 million option for underwriters. The funds will be used to advance late-stage clinical programs and expand commercial infrastructure. The offering is subject to market conditions and regulatory approvals.
Read more →RNAAvidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44
Avidity Biosciences announced positive results from the EXPLORE44 trials for del-zota, showing significant improvements in functional measures for patients with Duchenne muscular dystrophy (DMD). The treatment led to a notable reduction in creatine kinase levels and increased dystrophin production. Avidity plans to submit a Biologics License Application by the end of 2025.
Read more →RNAAvidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences, Inc. (Nasdaq: RNA) will participate in several upcoming investor conferences, showcasing its innovative RNA therapeutic platform. The company is revolutionizing RNA therapies with its Antibody Oligonucleotide Conjugates (AOCs) designed for specific muscle diseases. Their participation in these conferences indicates a growing interest in their clinical programs focused on myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. Avidity is also advancing therapies for rare genetic cardiomyopathies, further broadening its development pipeline.
Read more →RNAAvidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights
Avidity Biosciences reported strong financial results for the second quarter of 2025 and highlighted significant advancements in its clinical programs. The company is on track for three potential BLA submissions, including del-zota, del-brax, and del-desiran, with positive data supporting their efficacy. Avidity's financial stability is reinforced by a strong cash balance of approximately $1.2 billion, which is expected to fund operations through mid-2027. Additionally, the FDA granted Breakthrough Therapy designation for del-zota, showcasing regulatory momentum for its therapeutic candidates.
Read more →RNAAvidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission
Avidity Biosciences announced the completion of enrollment for the Phase 3 HARBOR trial of delpacibart etedesiran (del-desiran), aimed at treating myotonic dystrophy type 1 (DM1). Topline data are expected in Q2 2026, with marketing application submissions planned for H2 2026 across the U.S., EU, and Japan. Del-desiran is a potential first-ever approved treatment for this rare neuromuscular disease, targeting its genetic cause. Avidity has received several regulatory designations, enhancing the outlook for del-desiran's approval.
Read more →RNAAvidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
Avidity Biosciences has received FDA Breakthrough Therapy designation for delpacibart zotadirsen (del-zota) aimed at treating Duchenne muscular dystrophy (DMD) caused by mutations that allow for exon 44 skipping. The drug has shown promising results in increasing dystrophin production and improving biomarkers in ongoing clinical trials. A planned Biologics License Application (BLA) submission is set for the end of 2025, with commercial preparations already underway for a potential launch. The designations highlight the drug's potential to meet significant unmet medical needs in the DMD community.
Read more →RNAAvidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
Avidity Biosciences announced that it will present topline data from its Phase 1/2 FORTITUDE trial of delpacibart braxlosiran (del-brax) aimed at treating facioscapulohumeral muscular dystrophy (FSHD). The company has received FDA alignment on both accelerated and full approval pathways for the drug. Key presentations will take place at the 32nd Annual FSHD Society International Research Congress in Amsterdam, with prominent researchers highlighting new findings related to del-brax. This showcases Avidity's commitment to advancing RNA therapeutics for rare neuromuscular diseases.
Read more →RNA▼ -9.9%on this newsshared move
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
Avidity Biosciences announced that the FDA has opened the accelerated approval pathway for del-brax, a treatment for facioscapulohumeral muscular dystrophy (FSHD). The company has also initiated the global, confirmatory Phase 3 FORWARD study aimed at supporting a full approval package. Del-brax represents a significant advancement as it targets the underlying cause of FSHD, a condition currently lacking approved therapies. Avidity plans to submit a Biologics License Application in the second half of 2026 after obtaining topline data from the ongoing biomarker cohort in mid-2026.
Read more →RNA▼ -9.9%on this newsshared move
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
Avidity Biosciences has reported positive topline results from its Phase 1/2 FORTITUDE study of del-brax in patients with Facioscapulohumeral Muscular Dystrophy (FSHD). The data indicate improvements in muscle strength and mobility when compared to placebo, alongside significant reductions in biomarkers of muscle damage. With these encouraging outcomes, Avidity plans to submit a Biologics License Application (BLA) for accelerated approval in the second half of 2026. The company's findings will be presented at the upcoming FSHD Society International Research Congress.
Read more →RNAAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences has announced the grant of stock options and restricted stock units to 16 new employees under its 2022 Inducement Plan. This is part of a strategy to promote growth and attract talent in alignment with Nasdaq rules. The equity awards underscore Avidity's commitment to expanding its workforce and advancing its innovative RNA therapeutic platforms for rare diseases.
Read more →RNA▲ +9.6%on this news
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
Avidity Biosciences announced its first quarter 2025 financial results, showcasing progress in its late-stage clinical trials and commercial preparation. Notable advancements include positive topline data for del-zota and a cash position of approximately $1.4 billion, which supports ongoing R&D efforts. The company remains on track for a Biologics License Application by the end of 2025 and is preparing for a potential U.S. commercial launch in 2026. However, the company experienced a decrease in collaboration revenues year-over-year and rising operational costs.
Read more →RNA▼ -5.5%on this news
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences announced that its investigational treatment, delpacibart etedesiran (del-desiran), has received Orphan Drug designation from Japan's MHLW for myotonic dystrophy type 1 (DM1). This marks the first time a treatment for DM1 has achieved such designation in Japan. Del-desiran aims to address the root cause of this serious neuromuscular disease, for which no approved therapies currently exist. The company is progressing towards completion of enrollment for its Phase 3 HARBOR trial and anticipates moving forward with global marketing applications starting in 2026.
Read more →RNA▼ -6.6%on this newsshared move
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
Avidity Biosciences has completed enrollment in the biomarker cohort of its Phase 1/2 FORTITUDE trial for delpacibart braxlosiran (del-brax), aimed at treating facioscapulohumeral muscular dystrophy (FSHD). The company plans to share a regulatory update and topline data in Q2 2025, while pursuing an accelerated approval pathway in the U.S. Del-brax has shown promising initial data, demonstrating reductions in disease-related gene expression and favorable safety profiles. Avidity aims to be the first to deliver an approved treatment for FSHD, a condition lacking existing therapies.
Read more →RNA▲ +8.7%on this news
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
Avidity Biosciences, Inc. reported positive topline data from its Phase 1/2 EXPLORE44 trial regarding del-zota, an RNA therapeutic for Duchenne muscular dystrophy (DMD) amenable to exon 44 skipping. The data show statistically significant improvements in dystrophin production and creatine kinase levels along with favorable safety outcomes across multiple dose cohorts. The company plans to submit a Biologics License Application (BLA) by the end of 2025 and will present functional data in the fourth quarter of that year. Del-zota is set to be a groundbreaking treatment option for patients suffering from DMD.
Read more →RNA▲ +10.2%on this newsshared move
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences has announced its agenda for the upcoming 2025 Muscular Dystrophy Association Clinical & Scientific Conference, where it will present key findings from the EXPLORE44 trial. The company will showcase data demonstrating statistically significant increases in exon skipping and dystrophin levels from its del-zota treatment targeting Duchenne Muscular Dystrophy. Additionally, Avidity will host an industry forum breakfast and a live investor webcast discussing the trial results, highlighting its commitment to advancing RNA therapeutics through its innovative platform.
Read more →RNA▲ +5.4%on this news
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases
Avidity Biosciences, Inc. is commemorating Rare Disease Day by joining efforts to raise awareness for rare neuromuscular diseases and the need for more treatments. The company is participating in various initiatives, including supporting Rare Disease Week on Capitol Hill and sponsoring webinars focused on specific disorders. Avidity emphasizes its commitment to supporting the community affected by rare diseases, aiming to connect and inspire patients and families. Their innovative Antibody Oligonucleotide Conjugates (AOCs) therapeutic approach is showcased as a potential solution for previously untreatable conditions.
Read more →RNAAvidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights
Avidity Biosciences reported its fourth quarter 2024 financial results, highlighting significant progress in its clinical programs for rare neuromuscular diseases. Anticipating key milestones, the company is poised to submit its first Biologics License Application (BLA) for an Antibody Oligonucleotide Conjugate (AOC) in 2025. Avidity's financial strength, with approximately $1.5 billion in cash, supports its plans for multiple product launches targeting Duchenne muscular dystrophy and other conditions starting in 2026. The company is also addressing its research and development costs, which have increased markedly compared to the previous year.
Read more →RNAAvidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
Avidity Biosciences (Nasdaq: RNA) announced plans for a Biologics License Application (BLA) submission for del-zota by the end of 2025, focusing on treating Duchenne muscular dystrophy mutations amenable to exon 44 skipping. The company is also preparing for commercialization of therapies for myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy, and is enhancing its leadership team to facilitate growth. Upcoming key events include presentations at the annual J.P. Morgan Healthcare Conference and significant clinical milestones expected throughout 2025.
Read more →RNAAvidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
Avidity Biosciences has announced the development of two new precision cardiology candidates, AOC 1086 and AOC 1072, aimed at treating rare genetic cardiomyopathies. The preclinical data reveals that these candidates can deliver siRNA effectively to heart muscle, achieving an approximately 80% reduction in disease-causing mRNA levels. Additionally, next-generation technology innovations have been introduced, promising improved siRNA delivery and durability. The company plans to present data on AOC 1072 at the upcoming American Heart Association Scientific Sessions 2024.
Read more →RNAAvidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
Avidity Biosciences has reported its financial results for Q3 2024 alongside key updates on its clinical trials for del-desiran, del-zota, and del-brax. The company is currently executing three registrational clinical trials for rare diseases, with positive initial data reported. Enrollment for these trials remains on track, and Avidity has a strong financial foundation with approximately $1.6 billion in cash. The company is also gearing up to showcase its next-generation innovations and expand its commercial capabilities.
Read more →RNAAvidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
Avidity Biosciences, Inc. (RNA) has announced an upcoming investor and analyst event on November 12, 2024, to present new development candidates from its precision cardiology portfolio. The event will include a first look at next-generation technology innovations. Additionally, Avidity will present a poster on a lead precision cardiology candidate at the American Heart Association Scientific Sessions, scheduled for November 16, 2024. This marks an important step in advancing Avidity's pipeline in RNA therapeutics.
Read more →RNAAvidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy
Avidity Biosciences has initiated a biomarker cohort in the Phase 1/2 FORTITUDE trial for delpacibart braxlosiran (del-brax/AOC 1020), aiming for accelerated approval for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The company reported positive early results showing significant reductions in key biomarkers and potential functional improvements in patients. Enrollment in this cohort is expected to be completed by the first half of 2025, with plans to also initiate a functional cohort within the same timeframe. Del-brax represents a novel approach to directly addressing the root cause of FSHD, which currently has no approved treatments.
Read more →RNAAvidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
Avidity Biosciences announced that the FDA has lifted the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), allowing progress in its Phase 3 trial for myotonic dystrophy type 1 (DM1). The investigational therapy aims to address the cause of DM1 by targeting DMPK mRNA. With Breakthrough Therapy and Orphan Drug designations, del-desiran has shown promising long-term results in previous trials, specifically in reversing disease progression. The removal of the clinical hold positions Avidity to potentially provide a treatment for this severe and currently untreated condition.
Read more →RNAAvidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month
Avidity Biosciences is partnering with patient and advocacy communities to raise awareness during National Muscular Dystrophy Awareness Month. The company reported significant progress in its clinical programs, including data for myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy. Avidity has initiated a global Phase 3 study for its DM1 program and is actively engaging in multiple awareness and fundraising events throughout September. The company's innovative Antibody Oligonucleotide Conjugate platform aims to address the unmet needs of patients affected by these serious muscle disorders.
Read more →RNAAvidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters
Avidity Biosciences, Inc. has announced the successful closing of its upsized public offering, which consisted of 8,418,000 shares sold at $41.00 each. This offering raised approximately $345.1 million before deducting expenses, providing significant funding for the company's clinical programs and research in its Antibody Oligonucleotide Conjugates platform. The proceeds will support existing operations as well as advance developments in rare muscle diseases and other therapeutic areas.
Read more →RNA▲ +12.1%on this newsshared move
Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights
Avidity Biosciences reported strong quarterly results for Q2 2024, showcasing significant progress in their clinical trials and financial stability. Key highlights include positive data from the del-zota trial for DMD and the initiation of the global Phase 3 trial for del-desiran, which has been granted Breakthrough Therapy designation by the FDA. The company plans to accelerate development for multiple RNA therapeutic candidates while maintaining a robust cash position of approximately $1.3 billion. New appointments to its board signal strategic growth as they aim to expand into cardiology.
Read more →RNA▲ +12.1%on this newsshared move
Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44™ Trial
Avidity Biosciences announced positive data from its Phase 1/2 EXPLORE44 trial for AOC 1044 (delpacibart zotadirsen), showing a 25% increase in dystrophin production and a significant reduction in creatine kinase levels in patients with Duchenne muscular dystrophy. The 5 mg/kg dosage demonstrated improved delivery of phosphorodiamidate morpholino oligomers to skeletal muscle. No significant adverse events were reported, indicating favorable safety and tolerability. The trial's results may provide new treatment options for DMD patients, especially those with exon 44 skipping mutations.
Read more →RNAAvidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer
Avidity Biosciences has appointed John B. Moriarty, Jr. as the Chief Legal Officer, effective immediately. Moriarty, with nearly 30 years of legal expertise in biotechnology, succeeds John W. Wallen III, who will continue as a consultant until the end of the year. The company aims to leverage Moriarty's experience to enhance its clinical development programs for rare muscle diseases and expand its RNA therapeutic pipeline. Avidity is known for its innovative Antibody Oligonucleotide Conjugates (AOCs), designed to deliver RNA therapies effectively.
Read more →RNAAvidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day
Avidity Biosciences is collaborating with the FSHD Society to promote awareness of facioscapulohumeral muscular dystrophy (FSHD) on World FSHD Day. They are hosting a webinar to present positive data from the Phase 1/2 FORTITUDE trial for del-brax, an investigational therapy aimed at treating the underlying cause of FSHD. Initial findings show significant reductions in DUX4 regulated genes and favorable safety profiles. Avidity's efforts highlight their commitment to developing treatments for this rare, debilitating disease, linked with the support of the global FSHD patient community.
Read more →RNAAvidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters
Avidity Biosciences, Inc. has successfully closed an upsized public offering of 12,132,500 shares at $38.00 per share, generating approximately $461 million in gross proceeds. These funds are intended to support the development of clinical programs and advance the company's Antibody Oligonucleotide Conjugates (AOCs) platform. The offering included the full exercise of underwriters' options, reflecting significant investor interest. Avidity aims to use the proceeds for research and development, as well as for general corporate purposes.
Read more →RNAAvidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
Avidity Biosciences, Inc. has announced the pricing of a public offering of 10,550,000 shares of common stock at $38.00 each, expected to close on June 17, 2024. The gross proceeds from this offering are anticipated to reach $400.9 million, which will be utilized for the development of clinical programs and general corporate purposes. Notably, Avidity is known for its work on Antibody Oligonucleotide Conjugates (AOCs™), which target previously unreachable disease areas. The underwriters have also been granted an option to purchase additional shares, enhancing the overall funding potential for the company.
Read more →RNA▲ +32.6%on this newsshared move
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy
Avidity Biosciences has announced promising data for its investigational therapy AOC 1020, also known as delpacibart braxlosiran, from the Phase 1/2 FORTITUDE trial. The therapy showed over 50% reduction in DUX4 regulated genes and trends indicating functional improvements in patients with facioscapulohumeral muscular dystrophy (FSHD). The treatment displayed favorable safety and tolerability, with mild or moderate adverse events reported. Avidity plans to accelerate the initiation of registrational cohorts in the trial, highlighting the urgency to develop treatment options for FSHD patients, who currently have no available therapies.
Read more →RNA▲ +32.6%on this newsshared move
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
Avidity Biosciences, Inc. has announced a proposed underwritten public offering of $300 million in common stock, with an additional option for underwriters to purchase up to $45 million. The proceeds from this offering will be allocated to fund the development of clinical programs and enhancements to its Antibody Oligonucleotide Conjugates (AOCs) platform. The company emphasizes the inherent uncertainties associated with the timing and completion of the offering, highlighting the need for careful consideration of these factors.
Read more →RNAAvidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress
Avidity Biosciences will present preliminary data from its Phase 1/2 FORTITUDE trial involving AOC 1020 for facioscapulohumeral muscular dystrophy (FSHD) at the 31st Annual FSHD Society International Research Congress on June 13-14, 2024. Dr. Jeffrey M. Statland, a neurologist and investigator for the trial, will join Avidity's management for discussions during a live webcast on June 12, 2024. This event demonstrates Avidity's commitment to advancing its RNA therapeutics aimed at improving patient outcomes in rare muscular diseases.
Read more →RNAAvidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
Avidity Biosciences has appointed Simona Skerjanec to its board of directors, bringing nearly three decades of experience in the pharmaceutical industry. Her expertise in product commercialization and prior leadership roles at Roche and other major companies will support Avidity's goals of advancing RNA therapeutics. The appointment is timely as Avidity aims to expand its clinical programs for neuromuscular diseases and explore new therapeutic areas. However, the company faces potential risks related to clinical trials and the unproven nature of its platform.
Read more →RNAAvidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Avidity Biosciences reported its Q1 2024 financial results, highlighting significant progress in its clinical programs and a strong cash position of $915 million following a $400 million equity raise. The initiation of the global Phase 3 HARBOR trial for del-desiran is on track, with positive long-term data from the MARINA-OLE study showing reversal of disease progression in myotonic dystrophy type 1. The company anticipates upcoming data releases from its FORTITUDE and EXPLORE44 trials within the year, bolstering its clinical development efforts in rare muscle diseases.
Read more →RNAAvidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences announced that the FDA has granted Breakthrough Therapy designation to delpacibart etedesiran (AOC 1001) for treating myotonic dystrophy type 1. The designation highlights the urgency and potential of this investigational treatment for a disease currently lacking approved therapies. The company is set to initiate a global Phase 3 trial named HARBOR to further assess delpacibart etedesiran's efficacy and safety based on encouraging results from previous studies. Avidity has also received additional designations from the FDA and EMA to facilitate the drug's development.
Read more →RNA▼ -6.2%on this news
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
Avidity Biosciences has announced positive long-term data from its AOC 1001 (now delpacibart etedesiran) trial, showing a reversal of disease progression in patients with myotonic dystrophy type 1 (DM1). The data, which revealed consistent improvements across various endpoints, will inform the upcoming Phase 3 HARBOR trial expected to start in Q2 2024. This investigational treatment has demonstrated durable efficacy regarding muscle strength and daily activities, marking a significant advancement in addressing a previously untreated condition. Avidity is also hosting an investor event to discuss these promising findings.
Read more →RNA▲ +19.9%on this news· ran to +32% by day 1shared move
Avidity Biosciences Honors Rare Disease Day®
Avidity Biosciences (RNA) has marked Rare Disease Day by emphasizing its commitment to developing RNA therapeutics for rare diseases. The company is advancing clinical programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). CEO Sarah Boyce highlighted the urgency of their mission to improve patient lives through innovative therapies. However, Avidity also faces significant risks, including a clinical hold on one of its programs due to an adverse event.
Read more →RNA▲ +19.9%on this news· ran to +32% by day 1shared move
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
Avidity Biosciences has announced an oversubscribed private placement, raising approximately $400 million to support its RNA therapeutic programs. The financing, which will close on or about March 4, 2024, includes contributions from various institutional investors and will provide funding into late 2026. The company plans to use the proceeds for research and development, as well as operational purposes. A webcast event to discuss new clinical data from their AOC 1001 program is scheduled for March 4, 2024.
Read more →RNAAvidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
Avidity Biosciences has announced its fourth quarter and year-end 2023 financial results, highlighting a promising outlook with plans to initiate a global Phase 3 trial for AOC 1001 targeting myotonic dystrophy type 1 (DM1) in mid-2024. The company reported strong financial health with $595 million in cash and outlined upcoming data releases from its clinical programs for rare muscle diseases. Additionally, Avidity is set to share long-term efficacy and safety data from its ongoing MARINA-OLE™ trial in March 2024, as it continues to expand its innovative RNA therapeutic platform. The organization also recently expanded its collaboration with Bristol Myers Squibb, further solidifying its growth trajectory.
Read more →RNAAvidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
Avidity Biosciences announced that its investigational therapy AOC 1044 for Duchenne muscular dystrophy (DMD) has received FDA's Rare Pediatric Disease designation. This therapy targets mutations amenable to exon 44 skipping and is currently being evaluated in the Phase 1/2 EXPLORE44 trial. AOC 1044 has already garnered Orphan Drug and Fast Track Designations, indicating its potential significance in addressing unmet medical needs. Recent data from the trial showed impressive oligonucleotide delivery in skeletal muscle and consistent exon skipping in healthy volunteers, fueling optimism for its future use in treating DMD patients.
Read more →RNAAvidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences announced it will present long-term efficacy and safety data for AOC 1001, an RNA therapeutic targeted at myotonic dystrophy type 1 (DM1), at the 2024 MDA Clinical & Scientific Conference. The event is set to take place in Orlando, Florida, from March 3-6, 2024, where the company will also highlight findings from various clinical development programs addressing rare muscle diseases. This presentation will be led by John W. Day, MD, PhD, a notable researcher in the field. A live webcast will accompany the presentations, promoting broader access to the data.
Read more →RNAAvidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
Avidity Biosciences has announced its 2024 corporate priorities, focusing on advancing its clinical programs, including a global Phase 3 trial of AOC 1001 for myotonic dystrophy type 1 (DM1) set for mid-2024. The company will report data from its three ongoing clinical programs for rare muscle diseases throughout the year. Avidity also highlighted its expansion into cardiology and appointed Eric B. Mosbrooker as Chief Strategy Officer, emphasizing its commitment to delivering innovative RNA therapeutics.
Read more →RNA▲ +10.3%on this news· ran to +23% by day 3
Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular Dystrophy
Avidity Biosciences announced positive results from its Phase 1/2 EXPLORE44 trial, indicating that AOC 1044 achieved up to 50-times greater concentrations of PMO in skeletal muscle compared to standard treatments. The trial noted a statistically significant exon 44 skipping compared to the placebo group, representing a promising advancement in treating Duchenne muscular dystrophy. AOC 1044 was well tolerated among healthy participants, showing a good safety profile. Avidity plans to share data regarding the treatment's effects on patients with DMD44 in the second half of 2024.
Read more →RNA▲ +14.9%on this news· ran to +31% by day 3
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity
Avidity Biosciences has announced an expansion of its collaboration with Bristol Myers Squibb, under which it will focus on the discovery and development of cardiovascular targets. The deal provides Avidity with an upfront payment of $100 million, along with the potential to earn up to $2.3 billion in milestone payments and low double-digit royalties. This agreement aims to utilize Avidity's proprietary Antibody Oligonucleotide Conjugates (AOCs) platform, enhancing the company's strategic focus in cardiology while Bristol Myers Squibb will handle all clinical development and commercialization activities.
Read more →RNA▼ -7%on this news
Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights
Avidity Biosciences, Inc. reported its third quarter 2023 results, highlighting positive clinical data for its AOC 1001 treatment for myotonic dystrophy type 1 (DM1) presented at the World Muscle Society Congress. The company also received Orphan Designation for its AOC 1044 treatment for Duchenne muscular dystrophy (DMD). Financially, Avidity ended the quarter with $542.6 million in cash and reported increased collaboration revenue. However, the company continues to address a partial clinical hold on the AOC 1001 development program.
Read more →RNAAvidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1
Avidity Biosciences has released new data showcasing the positive effects of its AOC 1001 therapy for myotonic dystrophy type 1, highlighting significant improvements in functional measures such as muscle strength and patient-reported outcomes. The long-term safety profile remains favorable, with data collected from over 200 infusions reporting mostly mild to moderate adverse events. The company plans to present further data in 2024 and is finalizing the design for Phase 3 studies. The ongoing commitment to develop RNA therapeutics aims to address the unmet medical needs associated with this rare disease.
Read more →RNAAvidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society
Avidity Biosciences, Inc. has announced its participation in the 28th Annual Congress of the World Muscle Society taking place from October 3-7, 2023, in Charleston, South Carolina. The company will present one oral presentation and six posters, highlighting key data from clinical trials involving their Antibody Oligonucleotide Conjugates. Significant focus will be on the AOC 1001 therapy for Myotonic Dystrophy Type 1 with topline safety and efficacy data to be discussed. This underscores Avidity's commitment to advancing RNA therapeutics for rare muscle diseases.
Read more →RNAAvidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs
Avidity Biosciences is collaborating with patient communities to raise awareness during National Muscular Dystrophy Awareness Month. The company is advancing three clinical programs targeting myotonic dystrophy, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. As part of the awareness efforts, Avidity will engage in educational briefings and various events throughout September. The company's lead program, AOC 1001, is currently being studied with data expected in 2024.
Read more →RNA▼ -5.1%on this news
Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference
Avidity Biosciences, Inc. (Nasdaq: RNA) announced its participation in the 2023 Myotonic Dystrophy Foundation Annual Conference with two scheduled poster presentations. These presentations will showcase findings from a Phase 1/2 clinical trial evaluating AOC 1001 for myotonic dystrophy type 1. The conference is set to take place from September 7-9, 2023, in Washington, D.C. Avidity aims to improve lives through its revolutionary Antibody Oligonucleotide Conjugates (AOCs) platform, targeting rare muscle diseases.
Read more →RNAAvidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
Avidity Biosciences has received FDA Orphan Drug designation for AOC 1044, a therapy aimed at treating Duchenne muscular dystrophy in patients with mutations suitable for exon 44 skipping. This designation highlights the drug's potential to address a significant unmet medical need, as current therapies do not target exon 44. AOC 1044 is being evaluated in the Phase 1/2 EXPLORE44 clinical trial, with results anticipated later in 2023. The therapy leverages Avidity's innovative Antibody Oligonucleotide Conjugates platform, designed to enhance therapeutic specificity and effectiveness.
Read more →RNAAvidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights
Avidity Biosciences reported its second quarter 2023 financial results, highlighting progress in three clinical development programs for rare muscle diseases. With a robust cash reserve of $577 million, the company is well-positioned to advance its pipeline, which includes therapies AOC 1001, AOC 1020, and AOC 1044. Positive data from the MARINA trial has supported the company's endeavors, although they remain cautious due to a partial clinical hold in their development processes. Upcoming data releases are anticipated within the next 12 months, contributing to the company's mission of providing innovative RNA therapeutics.
Read more →RNAAvidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day
Avidity Biosciences is collaborating with patients, caregivers, and healthcare providers to support World FSHD Day while advancing its Phase 1/2 FORTITUDE trial of AOC 1020 for facioscapulohumeral muscular dystrophy (FSHD). The company aims to reduce the muscular impairment caused by the disease through targeted gene therapy. Preliminary data from the FORTITUDE study is expected in the first half of 2024. Despite the presence of the disease, the collaboration demonstrates hope for future treatment advancements.
Read more →RNAAvidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress
Avidity Biosciences, Inc. (Nasdaq: RNA) has announced its participation in the 30th Annual FSHD Society International Research Congress scheduled for June 15-16, 2023, in Milan, Italy. During the event, Avidity will deliver two oral presentations and present two posters that focus on its innovative Antibody Oligonucleotide Conjugates (AOCs) for Facioscapulohumeral Muscular Dystrophy (FSHD). This underscores Avidity's role in advancing RNA therapies to tackle rare muscle diseases and enhance patient care.
Read more →RNAAvidity Biosciences Announces FDA Eases Partial Clinical Hold on AOC 1001 Providing a Clear Path Forward to Finalize Pivotal Dose and Phase 3 Design in Adults with Myotonic Dystrophy Type 1
Avidity Biosciences announced that the FDA has eased the partial clinical hold on its product AOC 1001, allowing for an increase in participants in the MARINA Open-Label Extension study. This change permits the enrollment of new participants receiving 2 mg/kg and doubles the number of participants receiving 4 mg/kg. Avidity plans to use data from this study to finalize the pivotal dose and Phase 3 study design for adults with myotonic dystrophy type 1. Topline data from previous trials highlighted functional improvements, further enhancing the drug's potential to address this serious condition.
Read more →RNAAvidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
Avidity Biosciences reported its first quarter 2023 financial results, highlighting positive topline data from its AOC 1001 Phase 1/2 MARINA trial for myotonic dystrophy type 1. The data demonstrated functional improvements, disease modification, and a favorable safety profile. The company ended the quarter with $586.3 million in cash, positioning it well for future clinical development. However, AOC 1001 is currently under a partial clinical hold due to a serious adverse event, which the company is addressing with the FDA.
Read more →RNA▼ -16.1%on this news· ran to -36% by day 3
Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1
Avidity Biosciences announced positive topline data from the Phase 1/2 MARINA trial of AOC 1001, showing functional improvements in patients with myotonic dystrophy type 1 (DM1). Key endpoints demonstrated directionally positive results concerning myotonia, muscle strength, and mobility, alongside a favorable safety profile with mostly mild adverse events. However, the company is working to resolve a partial clinical hold on participant enrollment imposed by the FDA. Overall, the data collected have exceeded initial expectations and suggest promising implications for treatment options in DM1.
Read more →RNAAvidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
Avidity Biosciences has announced that its product AOC 1044 has been granted Fast Track designation by the FDA for treating Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping. This designation will facilitate expedited development and review processes due to the serious nature of the condition. The company is currently assessing AOC 1044 in the Phase 1/2 EXPLORE44 clinical trial and plans to share results from the healthy volunteer part of the trial later this year. AOC 1044 is the first in a series of Antibody Oligonucleotide Conjugates (AOCs) aimed at treating DMD.
Read more →RNA▲ +8.1%on this news
Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting
Avidity Biosciences announced it will present at the 75th American Academy of Neurology Annual Meeting in Boston from April 22-27, 2023. The company will share topline results from its Phase 1/2 MARINA trial evaluating AOC 1001 for myotonic dystrophy type 1 and discuss the design of the FORTITUDE trial for AOC 1020 targeting facioscapulohumeral muscular dystrophy. These developments underscore Avidity's ongoing commitment to advancing RNA therapeutics.
Read more →RNA▲ +9.1%on this newsshared move
Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA™ Trial on April 27, 2023
Avidity Biosciences will host an investor and analyst event on April 27, 2023, in Boston, to present topline data from its AOC 1001 Phase 1/2 MARINA trial targeting myotonic dystrophy type 1. The event, featuring lead investigator Nicholas E. Johnson, will be available via webcast, ensuring broader access to the findings. This marks the seventh volume of Avidity's ongoing series aimed at engaging with investors and analysts regarding their clinical developments in RNA therapeutics.
Read more →RNA▼ -16.8%on this news· ran to -29% by day 3
Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting
Avidity Biosciences has provided a regulatory update regarding AOC 1001 for myotonic dystrophy type 1 (DM1), revealing ongoing discussions with the FDA about a partial clinical hold due to a serious adverse event in a trial participant. Notably, preliminary data from the Phase 1/2 MARINA trial illustrates successful targeted RNA delivery and early clinical improvements. The top-line data will be presented at the AAN Annual Meeting on April 27, 2023, while Avidity plans to resolve the hold and move forward with AOC 1001's development.
Read more →RNAAvidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference
Avidity Biosciences, Inc. announced its participation in the 2023 MDA Clinical & Scientific Conference, where it will present two oral and several poster presentations. The presentations will cover developments in their Antibody Oligonucleotide Conjugates (AOCs™), specifically focusing on treatments for myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy. Among the highlighted topics is the ongoing Phase 1/2 MARINA™ trial for AOC 1001 and AOC 1020's potential for treating facioscapulohumeral muscular dystrophy. The company aims to revolutionize RNA therapeutics and improve patient outcomes.
Read more →RNAAvidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights
Avidity Biosciences, Inc. reported its fourth quarter and year-end 2022 financial results, highlighting progress in its RNA therapeutics pipeline. The company advanced three clinical programs, including successful RNA delivery to muscle and initiated trials for AOCs targeting rare diseases. With over $600 million in funding, Avidity is poised for significant advancements in its various programs, including AOC 1001, AOC 1020, and AOC 1044. The anticipated results from these trials, along with ongoing collaborations, mark a promising outlook for the company.
Read more →RNAAvidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ Platform
Avidity Biosciences Inc. is advancing its RNA therapeutic programs by expanding its internal discovery pipeline to include new treatments for skeletal muscle and cardiology. The company is currently executing three Phase 1/2 clinical programs targeting rare diseases such as myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy. Avidity is leveraging its proprietary Antibody Oligonucleotide Conjugates (AOCs) platform and aims to explore additional applications beyond muscle diseases. However, the company faces uncertainties regarding FDA approvals and potential adverse effects that might delay development.
Read more →RNAAvidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader
Avidity Biosciences has appointed Arthur A. Levin, Ph.D., to its Board of Directors while he transitions to the role of distinguished scientist and strategic leader. This change reflects the company's commitment to leveraging Levin's extensive expertise in RNA therapeutics to advance its Antibody Oligonucleotide Conjugate (AOC) platform. Additionally, W. Michael Flanagan, Ph.D., has been promoted to chief scientific and technical officer, indicating strong internal leadership continuity. The company aims to expand its clinical development programs amid ongoing challenges in the field.
Read more →RNAAvidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
Avidity Biosciences has received FDA Orphan Drug designation for AOC 1020, aimed at treating facioscapulohumeral muscular dystrophy (FSHD), a rare and serious genetic condition. The drug is currently being evaluated in the Phase 1/2 FORTITUDE clinical trial, with preliminary data expected to be shared in early 2024. AOC 1020 targets the DUX4 gene, believed to be central in the disease's pathology. The Orphan Drug status allows Avidity to benefit from various regulatory advantages as it seeks to develop a treatment for FSHD, which currently has no approved therapies.
Read more →RNAAvidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
Avidity Biosciences has announced that the FDA granted Fast Track designation to AOC 1020, aimed at treating Facioscapulohumeral Muscular Dystrophy (FSHD). This designation allows for expedited development due to the serious nature of the condition, which currently has no approved therapies. AOC 1020 is under investigation in the FORTITUDE trial, with preliminary data expected to be released in early 2024. The therapy targets the underlying genetic cause of FSHD, offering new hope for patients suffering from this debilitating disorder.
Read more →RNA▲ +6.5%on this news
Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, Dec. 15, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering
Read more →RNA▲ +55.3%on this news· ran to +66% by day 3shared move
Avidity Announces Positive AOC 1001 Phase 1/2 MARINA™ Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics
AOC 1001 delivered siRNA to skeletal muscle and produced meaningful DMPK reduction in 100% of participants with a 45% mean reduction in DMPK after a single dose of 1 mg/kg or two doses of 2 mg/kg AOC 1001 produced splicing improvement of 31% in a key set of muscle-specific genes
Read more →RNAAvidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights
Company has three distinct rare disease programs in clinical development - myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD) On track for preliminary assessment of AOC 1001 MARINA™ trial in fourth quarter SAN D
Read more →RNAAvidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
AOC 1044 is the first antibody oligonucleotide conjugate (AOC™) of multiple Duchenne muscular dystrophy programs to enter the clinic First AOC from Avidity's RNA platform technology engineered to deliver phosphorodiamidate morpholino oligomers (PMO) to enter the clinic Avidity
Read more →RNAAvidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle Society
SAN DIEGO, Oct. 6, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the company will be presenting five poster pres
Read more →RNAAvidity Biosciences Announces the Phase 1/2 FORTITUDE™ Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy
(PRNewsfoto/Avidity Biosciences, Inc.) AOC 1020 is Avidity's second siRNA antibody oligonucleotide conjugate (AOC™) entering Phase 1/2 studies Company now has three distinct rare disease programs in clinical development - myotonic dystrophy type 1 (DM1), facioscapulohumeral mus
Read more →RNA▼ -10.9%on this newsshared move
Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial
Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs now advancing into the clinic Company to host investor webcast today a
Read more →RNA▲ +10%on this news
Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs
Company remains on track to have three muscular dystrophy programs in clinic by end of year SAN DIEGO, Sept. 7, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligo
Read more →RNAAvidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
Company remains on track to have three programs in the clinic by the end of this year Programs are for three distinct rare diseases - myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD) SAN DIEGO, Aug. 9, 2022 /PR
Read more →RNA▲ +6%on this news· ran to +22% by day 3
Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study
(PRNewsfoto/Avidity Biosciences, Inc.) (PRNewsfoto/Avidity Biosciences, Inc.) Adults with myotonic dystrophy type 1 (DM1) in the AOC 1001 Phase 1/2 MARINA™ clinical trial can receive continuity of care as part of MARINA-OLE™ Preliminary assessment of safety, tolerability and k
Read more →RNA▲ +7.8%on this news· ran to +28% by day 3
Avidity Biosciences Supports World Facioscapulohumeral Muscular Dystrophy (FSHD) Day and Presents Preclinical Data from FSHD Program
Oral Presentation at FSHD IRC highlights preclinical data that demonstrated prevention of muscle weakness by reducing DUX4 expression AOC 1020 on track to be in the clinic by end of 2022 for the treatment of FSHD SAN DIEGO, June 17, 2022 /PRNewswire/ -- Avidity Biosciences, Inc
Read more →RNAAvidity Biosciences Announces Upcoming Presentations at the 29th Annual FSHD Society International Research Congress
SAN DIEGO, June 9, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting an oral and poster pres
Read more →RNAAvidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
SAN DIEGO, May 10, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the first quarter ended M
Read more →RNAAvidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer
SAN DIEGO, April 5, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Michael MacLean, currently the chief fina
Read more →RNA▲ +7.1%on this news
Avidity Biosciences Announces Upcoming Presentations at the American Academy of Neurology 2022 Annual Meeting
SAN DIEGO, March 29, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting at the American Acade
Read more →RNAAvidity Biosciences Announces Upcoming Presentations at the 2022 MDA Clinical & Scientific Conference
SAN DIEGO, March 7, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting an oral presentation a
Read more →RNAAvidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights
SAN DIEGO, March 1, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and ye
Read more →RNAAvidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer
SAN DIEGO, Feb. 23, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Steve Hughes, M.D. as chief
Read more →RNA▼ -7.1%on this news
Avidity Biosciences Highlights FSHD Program at Virtual Investor and Analyst Event
LA JOLLA, Calif., Dec. 9, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it will be hosting a live webcast invest
Read more →RNAAvidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
LA JOLLA, Calif., Nov. 9, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the third quarter a
Read more →RNA▲ +9%on this newsshared move
Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)
LA JOLLA, Calif., Nov. 4, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the first participants in the Phase
Read more →RNA▼ -5.2%on this news
FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
LA JOLLA, Calif., Oct. 18, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administrat
Read more →RNAAvidity Biosciences Announces Changes to its Board of Directors
LA JOLLA, Calif., Aug. 25, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of experienced global co
Read more →RNAEuropean Medicines Agency (EMA) Grants Orphan Designation for AOC 1001
LA JOLLA, Calif., Aug. 24, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced that the European Commission (EC) has granted
Read more →RNA▼ -6.9%on this news
Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use
LA JOLLA, Calif., Aug. 16, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its collaboration with the Facioscapulo
Read more →RNAAvidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
LA JOLLA, Calif., Aug. 9, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the second quarter
Read more →RNA▲ +6.8%on this newsshared move
Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)
(PRNewsfoto/Avidity Biosciences, Inc.) LA JOLLA, Calif., Aug. 2, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced
Read more →RNAAvidity Biosciences Announces Updates on the Pipeline and Platform at Virtual Investor and Analyst Event
LA JOLLA, Calif., May 19, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), announced that new preclinical data on its lead AOC pr
Read more →RNAAvidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights
LA JOLLA, Calif., May 12, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the first quarter
Read more →RNAAvidity Biosciences to Host Virtual Investor and Analyst Event on May 19, 2021
LA JOLLA, Calif., May 3, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it will host a virtual investor an
Read more →RNAAvidity Biosciences to Present Oral Presentation on AOC 1001 for DM1 at American Academy of Neurology (AAN) 2021 Virtual Annual Meeting
LA JOLLA, Calif., April 16, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that preclinical data for their lead
Read more →RNAAvidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights
LA JOLLA, Calif., March 15, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quar
Read more →RNAAvidity Biosciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference
LA JOLLA, Calif., Feb. 17, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Sarah Boyce, President and Chief
Read more →RNAAvidity Biosciences Appoints W. Michael Flanagan, Ph.D. as Chief Technical Officer
LA JOLLA, Calif., Jan. 21, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of W. Michael Flanaga
Read more →RNAAvidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia
LA JOLLA, Calif., Jan. 8, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced pipeline updates for 2021 and a resear
Read more →RNAAvidity Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
LA JOLLA, Calif., Dec. 22, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Sarah Boyce, President and Chief
Read more →RNAAvidity Biosciences Announces Addition to the Nasdaq Biotechnology Index
LA JOLLA, Calif., Dec. 21, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has been added to the Nasdaq
Read more →RNAAvidity Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights
LA JOLLA, Calif., Nov. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the quarter ende
Read more →RNAAvidity Biosciences to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020
LA JOLLA, Calif., Nov. 5, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Sarah Boyce, President and Chief
Read more →RNAAvidity Biosciences to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020
LA JOLLA, Calif., Sept. 28, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Sarah Boyce, President and Chie
Read more →RNAAvidity Biosciences to Present at Several Upcoming Virtual Scientific Meetings
SAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will present at several up
Read more →RNAAvidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1
SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced it entered into a collaboration supporting E
Read more →RNAAvidity Biosciences to Present at the 2020 Wells Fargo Virtual Healthcare Conference
SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Sarah Boyce, Avidity's President and CE
Read more →RNAAvidity Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
SAN DIEGO, Aug. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the quarter and six mon
Read more →RNAAvidity Biosciences Appoints Jae Kim, M.D. as Chief Medical Officer
SAN DIEGO, July 27, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Jae Kim, M.D. as Chief Me
Read more →RNAAvidity Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters
SAN DIEGO, June 16, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the closing of its initial public offering o
Read more →RNAAvidity Biosciences Announces Pricing of Initial Public Offering
SAN DIEGO, June 11, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its initial public offering of
Read more →RNAAvidity Biosciences Appoints Michael MacLean as Chief Financial Officer
SAN DIEGO, May 19, 2020 /PRNewswire/ -- Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Michael MacLean as Chief Financial Officer. "Mike is a leader who has succ
Read more →RNAAvidity Biosciences Appoints Carsten Boess to its Board of Directors
SAN DIEGO, April 13, 2020 /PRNewswire/ -- Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Carsten Boess to its board of directors. Mr. Boess, who has nearly thirty
Read more →RNAAvidity Biosciences Announces Presentations at Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- Avidity Biosciences (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today that Sarah Boyce, Avidity's President and CEO, will present a company overview at two upcoming in
Read more →RNAAvidity Biosciences Appoints Joseph Baroldi as Chief Operating Officer
SAN DIEGO, Feb. 12, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Joseph Baroldi as Chief Operating Officer. "We are thrilled to welcome
Read more →RNAAvidity Biosciences Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 7, 2020 /PRNewswire/ -- Avidity Biosciences (Avidity) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020 in San Francisco, CA. Sarah Boyce, President and CEO of Avidity, will present an overvie
Read more →RNAAvidity Biosciences Appoints Sarah Boyce as Chief Executive Officer
LA JOLLA, Calif., Oct. 1, 2019 /PRNewswire/ -- Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of global business leader Sarah Boyce as President and Chief Executive Officer and a
Read more →RNAAvidity Biosciences to Present at the 2019 Myotonic Annual Conference
LA JOLLA, Calif., Sept. 12, 2019 /PRNewswire/ -- Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), today announced that Arthur A. Levin, Ph.D., Chief Scientific Officer, is scheduled to present at the 2019 Myotonic
Read more →Competitive Position
How RNA ranks across every disease it competes inCompetitive Position is a premium feature
See how RNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial